United States
MPI Research is a preclinical service provider catering to a diverse range of industries including agricultural, environmental, biopharmaceutical, medical device, animal health, and chemical sectors. Operating as A Charles River Company, MPI Research has established itself as a key player in conducting a multitude of studies encompassing small and large molecules across various compound classes. Their scope includes studies with numerous species and models, excluding inhalation routes of administration, showcasing their comprehensive offerings.
In addition to preclinical services, MPI Research has a strong emphasis on efficacy testing and a noteworthy presence in cellular and molecular biology, biomarkers, and gene therapy. Their substantial physical and technical capacity allows them to accommodate multiple requirements simultaneously, with the flexibility to adjust schedules and deliver rapid results. Notably, MPI Research Study Directors and Scientists are known for their accessibility and diligence in keeping Sponsors informed throughout the program cycle, from initial design collaboration to the final report.
Established in 1995 and headquartered in the United States, MPI Research has been at the forefront of providing a comprehensive spectrum of services for new drug and device candidates. Although specific details about their recent investment are not available, their consistent expansion and integration of services showcase a promising trajectory for potential investors.
For those seeking to delve deeper into the capabilities of MPI Research and explore their contributions to the healthcare and pharmaceutical industries, visiting their website at www.mpiresearch.com can provide further insights into their offerings and expertise.
